CMPS May 2024 12.500 call
| Previous Close | 0.0300 |
| Open | 0.0300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 12.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.0300 - 0.0300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 408 |
Insider MonkeyCOMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript May 11, 2024 COMPASS Pathways plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to the COMPASS Pathways’ First Quarter 2024 Earning Investor Call […]
GlobeNewswireCompass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8
- GlobeNewswire
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12 Measures of symptom score
